News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.

Image
Image

Media Contact:

Robert Murphy

Director, External Communications,
Otsuka America Pharmaceutical, Inc

Phone:
Email:
robert.murphy@otsuka-us.com
US News

People living with serious mental illness (SMI) are at higher risk for a wide range of chronic physical conditions, are more likely to visit the emergency department, be admitted to the hospital and have longer hospital stays compared to those without SMI. Nonadherence to drug treatments for major depressive disorder (MDD), schizophrenia and bipolar disorder is common. Several studies illustrate the problem, estimating that up to half of patients with bipolar disorder, MDD and/or schizophrenia do not take their medication as directed.

Press Release

Otsuka and Lundbeck presented positive results from a Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia at the 2022 Alzheimer's Association International Conference.

 

  • Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo
  • Agitation is a very prevalent clinical manifestation in Alzheimer’s dementia and one of the most complex and stressful aspects of care in patients affected by the disease. It is associated with greater caregiver burden, earlier nursing home placement, increased morbidity and mortality, and a substantial economic burden.
  • Currently there are no FDA-approved pharmacological treatments for agitation in Alzheimer’s dementia
Press Release

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce positive results of the Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia (NCT03548584). The analysis concluded that there is a statistically significant difference (p=0.0026) in the mean change from baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) total score between brexpiprazole and placebo.